HLA class II loss and JAK1/2 deficiency coevolve in melanoma leading to CD4 T cell and IFNγ cross-resistance.
Simone StupiaChristina HeekeAlicia BrüggemannAnne ZarembaBeatrice ThierJulia KretzAntje SuckerManuel PhilipGennadiy ZelinskyySoldano FerroneAlexander RoeschSusanne HornEva HadaschikDirk SchadendorfMirko TrillingUlf DittmerKlaus Georg GriewankFang ZhaoAnnette PaschenPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Our study links melanoma resistance to CD4 T cells, IFNγ, and ICB at the level of HLA-II, highlighting the significance of tumor cell-intrinsic HLA-II antigen presentation in disease control and calling for strategies to overcome its downregulation for improvement of patient outcome.